The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies

Ruiqi Meng, Joan E. Smallshaw, Laurentiu M. Pop, Michael Yen, Xiaoyun Liu, Lien Le, Maria Ana Ghetie, Ellen S. Vitetta, Victor Ghetie

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to prepare chimeric antihuman CD22 tetravalent monoclonal antibodies (MAbs) with high functional affinity, long persistence in the circulation, increased antitumor activity, and conserved effector function in vitro. Experimental Design: We investigated the association/ dissociation rates of these tetravalent antibodies using CD22 + Daudi lymphoma cells. We then tested their ability to interact with Fc receptors on a human cell line (U937), to mediate antibody-dependent cellular cytotoxicity with human natural killer cells, to bind human C1q, to inhibit the in vitro growth of CD22 Daudi cells, and to persist in the circulation. Results: The rate of dissociation of the tetravalent MAbs versus the divalent antibody was considerably slower. These tetravalent MAbs inhibited the in vitro proliferation of CD22 Daudi cells at a concentration that was at least 100-fold lower than that of the divalent murine antibody. The tetravalent MAbs containing both the CH2 and CH3 domains and a chimeric recombinant divalent antibody bound similarly to Fc receptor, C1q, and mediate antibody-dependent cellular cytotoxicity equally well with human natural killer cells. The persistence in the circulation of chimeric tetravalent MAbs was considerably longer than that of chemical homodimers. Conclusions: The tetravalent anti-CD22 MAbs with intact Fc regions should make effective therapeutic agents for B-cell tumors.

Original languageEnglish (US)
Pages (from-to)1274-1281
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number4
DOIs
StatePublished - Feb 15 2004

Fingerprint

Monoclonal Antibodies
Antibodies
Fc Receptors
Natural Killer Cells
Lymphoma
B-Lymphocytes
Research Design
Cell Line
Growth
In Vitro Techniques
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies. / Meng, Ruiqi; Smallshaw, Joan E.; Pop, Laurentiu M.; Yen, Michael; Liu, Xiaoyun; Le, Lien; Ghetie, Maria Ana; Vitetta, Ellen S.; Ghetie, Victor.

In: Clinical Cancer Research, Vol. 10, No. 4, 15.02.2004, p. 1274-1281.

Research output: Contribution to journalArticle

Meng, Ruiqi ; Smallshaw, Joan E. ; Pop, Laurentiu M. ; Yen, Michael ; Liu, Xiaoyun ; Le, Lien ; Ghetie, Maria Ana ; Vitetta, Ellen S. ; Ghetie, Victor. / The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 4. pp. 1274-1281.
@article{c46ee18454f54c418dff8c3d0083303d,
title = "The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies",
abstract = "Purpose: The purpose of this study was to prepare chimeric antihuman CD22 tetravalent monoclonal antibodies (MAbs) with high functional affinity, long persistence in the circulation, increased antitumor activity, and conserved effector function in vitro. Experimental Design: We investigated the association/ dissociation rates of these tetravalent antibodies using CD22 + Daudi lymphoma cells. We then tested their ability to interact with Fc receptors on a human cell line (U937), to mediate antibody-dependent cellular cytotoxicity with human natural killer cells, to bind human C1q, to inhibit the in vitro growth of CD22 Daudi cells, and to persist in the circulation. Results: The rate of dissociation of the tetravalent MAbs versus the divalent antibody was considerably slower. These tetravalent MAbs inhibited the in vitro proliferation of CD22 Daudi cells at a concentration that was at least 100-fold lower than that of the divalent murine antibody. The tetravalent MAbs containing both the CH2 and CH3 domains and a chimeric recombinant divalent antibody bound similarly to Fc receptor, C1q, and mediate antibody-dependent cellular cytotoxicity equally well with human natural killer cells. The persistence in the circulation of chimeric tetravalent MAbs was considerably longer than that of chemical homodimers. Conclusions: The tetravalent anti-CD22 MAbs with intact Fc regions should make effective therapeutic agents for B-cell tumors.",
author = "Ruiqi Meng and Smallshaw, {Joan E.} and Pop, {Laurentiu M.} and Michael Yen and Xiaoyun Liu and Lien Le and Ghetie, {Maria Ana} and Vitetta, {Ellen S.} and Victor Ghetie",
year = "2004",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-1154-03",
language = "English (US)",
volume = "10",
pages = "1274--1281",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies

AU - Meng, Ruiqi

AU - Smallshaw, Joan E.

AU - Pop, Laurentiu M.

AU - Yen, Michael

AU - Liu, Xiaoyun

AU - Le, Lien

AU - Ghetie, Maria Ana

AU - Vitetta, Ellen S.

AU - Ghetie, Victor

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Purpose: The purpose of this study was to prepare chimeric antihuman CD22 tetravalent monoclonal antibodies (MAbs) with high functional affinity, long persistence in the circulation, increased antitumor activity, and conserved effector function in vitro. Experimental Design: We investigated the association/ dissociation rates of these tetravalent antibodies using CD22 + Daudi lymphoma cells. We then tested their ability to interact with Fc receptors on a human cell line (U937), to mediate antibody-dependent cellular cytotoxicity with human natural killer cells, to bind human C1q, to inhibit the in vitro growth of CD22 Daudi cells, and to persist in the circulation. Results: The rate of dissociation of the tetravalent MAbs versus the divalent antibody was considerably slower. These tetravalent MAbs inhibited the in vitro proliferation of CD22 Daudi cells at a concentration that was at least 100-fold lower than that of the divalent murine antibody. The tetravalent MAbs containing both the CH2 and CH3 domains and a chimeric recombinant divalent antibody bound similarly to Fc receptor, C1q, and mediate antibody-dependent cellular cytotoxicity equally well with human natural killer cells. The persistence in the circulation of chimeric tetravalent MAbs was considerably longer than that of chemical homodimers. Conclusions: The tetravalent anti-CD22 MAbs with intact Fc regions should make effective therapeutic agents for B-cell tumors.

AB - Purpose: The purpose of this study was to prepare chimeric antihuman CD22 tetravalent monoclonal antibodies (MAbs) with high functional affinity, long persistence in the circulation, increased antitumor activity, and conserved effector function in vitro. Experimental Design: We investigated the association/ dissociation rates of these tetravalent antibodies using CD22 + Daudi lymphoma cells. We then tested their ability to interact with Fc receptors on a human cell line (U937), to mediate antibody-dependent cellular cytotoxicity with human natural killer cells, to bind human C1q, to inhibit the in vitro growth of CD22 Daudi cells, and to persist in the circulation. Results: The rate of dissociation of the tetravalent MAbs versus the divalent antibody was considerably slower. These tetravalent MAbs inhibited the in vitro proliferation of CD22 Daudi cells at a concentration that was at least 100-fold lower than that of the divalent murine antibody. The tetravalent MAbs containing both the CH2 and CH3 domains and a chimeric recombinant divalent antibody bound similarly to Fc receptor, C1q, and mediate antibody-dependent cellular cytotoxicity equally well with human natural killer cells. The persistence in the circulation of chimeric tetravalent MAbs was considerably longer than that of chemical homodimers. Conclusions: The tetravalent anti-CD22 MAbs with intact Fc regions should make effective therapeutic agents for B-cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=1642286792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642286792&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-1154-03

DO - 10.1158/1078-0432.CCR-1154-03

M3 - Article

VL - 10

SP - 1274

EP - 1281

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -